Edwards Lifesciences (EW) PT Raised to $157.00

Edwards Lifesciences (NYSE:EW) had its target price increased by equities research analysts at Morgan Stanley from $150.00 to $157.00 in a research report issued to clients and investors on Thursday, Stock Target Advisor reports. The firm presently has an “overweight” rating on the medical research company’s stock. Morgan Stanley’s price target indicates a potential upside of 9.49% from the company’s previous close.

Other equities analysts have also issued reports about the stock. Zacks Investment Research raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $165.00 price objective on the stock in a research report on Saturday, July 14th. Guggenheim reissued a “buy” rating and issued a $170.00 price objective on shares of Edwards Lifesciences in a research report on Friday, July 27th. Jefferies Financial Group reissued a “buy” rating and issued a $168.00 price objective on shares of Edwards Lifesciences in a research report on Friday, July 27th. ValuEngine raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Wednesday, September 19th. Finally, SunTrust Banks dropped their price objective on shares of Edwards Lifesciences to $170.00 and set a “buy” rating on the stock in a research report on Friday, August 10th. One research analyst has rated the stock with a sell rating, six have given a hold rating and fifteen have issued a buy rating to the company’s stock. Edwards Lifesciences presently has a consensus rating of “Buy” and a consensus price target of $155.30.

NYSE EW opened at $143.39 on Thursday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.47 and a current ratio of 1.86. Edwards Lifesciences has a 1 year low of $100.20 and a 1 year high of $175.00. The firm has a market cap of $36.45 billion, a price-to-earnings ratio of 37.50, a PEG ratio of 2.41 and a beta of 0.56.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, July 26th. The medical research company reported $1.24 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.13 by $0.11. Edwards Lifesciences had a net margin of 19.59% and a return on equity of 29.11%. The firm had revenue of $972.00 million for the quarter, compared to analyst estimates of $968.32 million. During the same period in the prior year, the firm posted $1.08 earnings per share. The company’s quarterly revenue was up 10.0% compared to the same quarter last year. Equities research analysts anticipate that Edwards Lifesciences will post 4.67 EPS for the current year.

In related news, VP Donald E. Bobo, Jr. sold 5,500 shares of the company’s stock in a transaction dated Wednesday, October 10th. The shares were sold at an average price of $147.50, for a total value of $811,250.00. Following the transaction, the vice president now directly owns 25,490 shares in the company, valued at $3,759,775. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Larry L. Wood sold 6,300 shares of the company’s stock in a transaction dated Monday, July 16th. The shares were sold at an average price of $148.02, for a total transaction of $932,526.00. Following the completion of the transaction, the vice president now owns 121,950 shares in the company, valued at $18,051,039. The disclosure for this sale can be found here. Insiders sold 158,811 shares of company stock worth $22,738,863 over the last 90 days. 1.84% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in EW. Commonwealth Equity Services LLC grew its stake in Edwards Lifesciences by 11.9% during the first quarter. Commonwealth Equity Services LLC now owns 26,399 shares of the medical research company’s stock worth $3,683,000 after buying an additional 2,816 shares in the last quarter. Lord Abbett & CO. LLC grew its stake in Edwards Lifesciences by 32.4% during the first quarter. Lord Abbett & CO. LLC now owns 113,065 shares of the medical research company’s stock worth $15,775,000 after buying an additional 27,667 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in Edwards Lifesciences by 5.1% during the first quarter. The Manufacturers Life Insurance Company now owns 234,093 shares of the medical research company’s stock worth $32,661,000 after buying an additional 11,344 shares in the last quarter. United Capital Financial Advisers LLC grew its stake in Edwards Lifesciences by 185.9% during the first quarter. United Capital Financial Advisers LLC now owns 24,001 shares of the medical research company’s stock worth $3,349,000 after buying an additional 15,607 shares in the last quarter. Finally, Natixis grew its stake in Edwards Lifesciences by 138.3% during the first quarter. Natixis now owns 37,446 shares of the medical research company’s stock worth $5,224,000 after buying an additional 21,733 shares in the last quarter. Hedge funds and other institutional investors own 82.10% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Read More: What Is An Exchange-Traded Fund (ETF)?

Stock Target Advisor

Analyst Recommendations for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply